Table 2 Time-course effects of SM1044 and DHA on cell viability in six types of human endometrial cancer cells. Data were presented as IC50 value (μM) with 95% confidence interval (95% CI). Experiments were performed in triplicate each time and independently repeated three times with different passages of cells.

From: Novel dihydroartemisinin dimer containing nitrogen atoms inhibits growth of endometrial cancer cells and may correlate with increasing intracellular peroxynitrite

Tested compounds

Cell Line

Inhibitory Potency IC50 (95%CI) μM

3 h

6 h

12 h

24 h

48 h

SM044

RL95-2

2.06b (0.39~10.78)

0.69a,d (0.24~2.01)

1.14

(0.27~4.77)

2.13b (0.98~4.62)

1.05 (0.23~4.84)

KLE

2.50 (1.38~4.51)

1.16 (0.32~4.22)

1.52

(0.55~ 4.22)

2.43 (0.42~14.06)

1.78 (0.43~7.37)

HEC-50

1.75 (0.28~11.10)

1.82 (0.29~11.47)

1.34

(0.35~5.08)

1.95 (0.79~4.77)

1.41 (0.67~2.95)

HEC-1-A

3.60c (1.16~11.23)

1.39 (0.35~5.52)

1.21a

(0.44~3.31)

2.73 (0.48~15.39)

2.21 (0.85~5.73)

HEC-1-B

1.95 (0.40~9.56)

1.80 (0.34~9.56)

2.00

(0.43~9.19)

1.84 (0.57~5.87)

1.41 (0.38~5.24)

AN3CA

3.22b (0.70~14.76)

1.14a (0.31~4.140)

1.87

(0.53~6.57)

2.62 (0.71~9.74)

1.46 (0.25~8.53)

DHA

RL95-2

 

59.74* (10.51~339.6)

36.65*

(18.17 ~73.95)

  

KLE

 

20.29*

(5.23~78.82)

19.95*

(17.98~22.13)

  

HEC-50

 

61.14* (40.51~92.27)

18.93*

(2.88~124.6)

  

HEC-1-A

 

39.34*

(0.42~ 3668)

26.88*

(0.34 ~2143)

  

HEC-1-B

 

77.02*

(5.12~ 1158)

74.85* (56.53~99.09)

  

AN3CA

 

82.37* (17.40~390.0)

44.29*

(6.06~323.4)

  
  1. aP < 0.05 vs SM1044 treatment for 3 h. bP < 0.05 vs SM1044 treatment for 6 h. cP < 0.05 vs SM1044 treatment for 12 h. dP < 0.05 vs SM1044 treatment for 24 h. *P < 0.05 vs SM1044 treatment at all time-point. Comparisons were conducted in the same cell lines.
Back to article page